The Australian Government has an extensive stockpile of antivirals (neuraminidase inhibitors) to be used if an influenza pandemic occurs.
Neuraminidase inhibitors reduce the duration of the symptoms of seasonal influenza infection by 1 day on average, when used as treatment within 48 hours of disease onset.
Neuraminidase inhibitors prevent infection in up to 74% of people when administered as prophylaxis.
Resistance of seasonal influenza viruses to neuraminidase inhibitors is low.
The safety and efficacy (including resistance) of neuraminidase inhibitors against pandemic influenza or the virus of current concern in pandemic planning, influenza A/H5N1, is not known, and further research is needed.
- 1. Australian Government Department of Health and Ageing. Australian health management plan for pandemic influenza. Canberra: Department of Health and Ageing, 2006. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ohp-pandemic-ahmppi.htm (accessed Sep 2006).
- 2. Beigel JH, Farrar J, Han AM, et al; Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353: 1374-1385.
- 3. Hien TT, Liem NT, Dung NT, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350: 1179-1188.
- 4. Wong SSY, Yuen K. Avian influenza virus infections in humans. Chest 2006; 129: 156-168.
- 5. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. 16 October 2006. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_10_16/en/index.html (accessed Oct 2006).
- 6. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353: 1363-1372.
- 7. Roche Products Pty Ltd. Tamiflu (oseltamivir phosphate) product information. Sydney: Roche, 2005. http://www.roche-australia.com/downloads/tamiflu-pi.cfm (accessed Oct 2006).
- 8. GlaxoSmithKline Australia. Relenza rotadisk product information. Melbourne: GlaxoSmithKline, 2006. http://www.gsk.com.au/products_prescription-medicines_detail.aspx?view=133 (accessed Oct 2006).
- 9. Jefferson TO, Demicheli V, Di Pietrantonj C, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2006; (3): CD001265.
- 10. Matheson JJ, Symmonds-Abrahams M, Sheikh A, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2003; (3): CD002744.
- 11. Peters PH, Gravenstein S, Norwood P, et al. Long term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49: 1025-1031.
- 12. World Health Organization. Rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. http://www.who.int/csr/disease/avian_influenza/guidelines/pharmamanagement/en/index.html (accessed Jul 2006).
- 13. Hayden FG. Antiviral resistance in influenza viruses — implications for management and pandemic response. N Engl J Med 2006; 354: 785-788.
- 14. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006; (2): CD001169.
- 15. Hayden FG. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res 2006; 71: 372-378.
- 16. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1139-1140.
- 17. de Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-2672.
- 18. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50: 2395-2402.
- 19. Hayden F, Klimov A, Tahiro M, et al. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther 2005; 10: 873-877. Erratum in Antivir Ther 2006; 11: 130.
- 20. Hayden FG. Pandemic influenza: is an antiviral response realistic? Pediatr Infect Dis J 2004; 23 (11 Suppl): S262-S269.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.